<SEC-DOCUMENT>0001125345-20-000160.txt : 20201216
<SEC-HEADER>0001125345-20-000160.hdr.sgml : 20201216
<ACCEPTANCE-DATETIME>20201216172736
ACCESSION NUMBER:		0001125345-20-000160
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20201216
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20201216
DATE AS OF CHANGE:		20201216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		201393409

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mgnx-20201216.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:defe0dfc-b2b5-41eb-a804-8da8c22404f1,g:2b135c73-87ba-4a09-9f73-64d843511717,d:97d706d7e7854443ada78c1b18b90c9a--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20201216</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV80L2ZyYWc6ZjE5ZTM4ZDIxOTQ3NDJhNWFhMDA5MjE0MWIxMTczOWEvdGFibGU6NmZkNTNjNmRiM2IzNDViMDkzNTE2MzAwYzhkOGVlNTUvdGFibGVyYW5nZTo2ZmQ1M2M2ZGIzYjM0NWIwOTM1MTYzMDBjOGQ4ZWU1NV8yLTEtMS0xLTA_4de58ee8-1795-4a5f-b37b-f9ccd6acbe84">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV80L2ZyYWc6ZjE5ZTM4ZDIxOTQ3NDJhNWFhMDA5MjE0MWIxMTczOWEvdGFibGU6NmZkNTNjNmRiM2IzNDViMDkzNTE2MzAwYzhkOGVlNTUvdGFibGVyYW5nZTo2ZmQ1M2M2ZGIzYjM0NWIwOTM1MTYzMDBjOGQ4ZWU1NV8zLTEtMS0xLTA_46eec113-fea7-44b2-bc12-4906c7ce5343">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20201216.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-16</xbrli:startDate><xbrli:endDate>2020-06-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i97d706d7e7854443ada78c1b18b90c9a_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ5_e4c15bbe-5517-4b79-a2dc-f465d2ad63e8">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8yMzI_8d982d2f-37e1-48cb-ac2c-fb90385c03f1">December 16, 2020</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjUw_19fe86e0-2e56-44e3-b5b7-8abc83acf0a8">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Exact Name of Registrant as Specified in Charter)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.948%"><tr><td style="width:1.0%"></td><td style="width:18.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl8wLTAtMS0xLTA_4074cb7c-80f7-4740-bdae-6ad89555964c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl8wLTMtMS0xLTA_e6c621fa-49a8-4984-b9e3-12aa6ad12e55">001-36112</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl8wLTUtMS0xLTA_016b92ca-98b5-4701-83d4-e07e1dff6857">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl8zLTAtMS0xLTA_b3f1a7fe-0c80-4bb0-ad4d-8c1035811fbf">9704 Medical Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl80LTAtMS0xLTA_20aeeec2-ddbd-421d-8a69-35d28a341c1d">Rockville,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl80LTEtMS0xLTA_a0a3867c-a539-4dfc-b26f-88f6a576271d">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl80LTMtMS0xLTA_4515f784-93ed-432f-99ef-d238214e6418">20850</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ2_88e9ca61-7427-4307-801e-d1f465774bc4">301</ix:nonNumeric>) <ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ3_40d7ff8e-c1ac-488c-94e5-ed509c9bfed0">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;padding-right:15.75pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6ZTZmNGM4Y2UwZjEzNDVkYWFlMTZlNTA2MTc5N2I5ZmEvdGFibGVyYW5nZTplNmY0YzhjZTBmMTM0NWRhYWUxNmU1MDYxNzk3YjlmYV8xLTAtMS0xLTA_e970cd82-c104-4e86-bff3-5d9386d92280">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6ZTZmNGM4Y2UwZjEzNDVkYWFlMTZlNTA2MTc5N2I5ZmEvdGFibGVyYW5nZTplNmY0YzhjZTBmMTM0NWRhYWUxNmU1MDYxNzk3YjlmYV8xLTEtMS0xLTA_c48716b2-2061-43ac-b981-489c24aaec89">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6ZTZmNGM4Y2UwZjEzNDVkYWFlMTZlNTA2MTc5N2I5ZmEvdGFibGVyYW5nZTplNmY0YzhjZTBmMTM0NWRhYWUxNmU1MDYxNzk3YjlmYV8xLTItMS0xLTA_d8905fc2-c4e1-4f6a-aea6-6ff2c0c371e0">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ0_afca1318-c3a1-480b-9e27-d5821fcb1f33">&#9744;</ix:nonNumeric> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ4_fdc7c2bf-de13-4ba4-866f-0e8182afc471">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ1_de81a556-534b-4b80-8a48-1231935b6e69">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQy_38654b7b-4bd5-421a-84a4-160c72964281">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQz_d4578305-f255-4db0-810e-020bf955273e">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i97d706d7e7854443ada78c1b18b90c9a_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Events</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 16, 2020, MacroGenics, Inc.&#8239;(the &#8220;Company&#8221;) issued a press release announcing that the U.S. Food and Drug Administration has approved the Company&#8217;s Biologics License Application for MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (margetuximab-cmkb), in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.  A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div><span><br/></span></div><div id="i97d706d7e7854443ada78c1b18b90c9a_10"></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Exhibits</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(d) Exhibits.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="margenzaapprovalpressrelea.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="margenzaapprovalpressrelea.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="margenzaapprovalpressrelea.htm">D</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="margenzaapprovalpressrelea.htm">ecember 16, 2020</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div id="i97d706d7e7854443ada78c1b18b90c9a_13"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:44.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  December 16, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and General Counsel</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>margenzaapprovalpressrelea.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i8e2e80628f76434ca0f8ac3e0f493ca5_1"></div><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:0.08pt"><img alt="image_11.jpg" src="image_11.jpg" style="height:84px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 99.1</font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Announces FDA Approval of MARGENZA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> for Patients with Pretreated Metastatic HER2-Positive Breast Cancer </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.15pt">MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin&#174; (trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.15pt">MARGENZA is approved, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.15pt">Product launch anticipated in March of 2021</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.15pt">Conference call scheduled for Thursday, December 17, 2020 at 8&#58;00 a.m. ET</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROCKVILLE, MD, December 17, 2020 -- MacroGenics, Inc.&#160;(Nasdaq&#58; MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA , in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. </font><font style="color:#333333;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MARGENZA is the first product approved from MacroGenics&#8217; promising pipeline</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The approval was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The approval of MARGENZA is an exciting milestone for MacroGenics and, more importantly, it brings a new treatment option to metastatic breast cancer patients. We are grateful for the patients who participated in this study, as well as their families,&#160;and everyone who played a role in helping MacroGenics reach this milestone,&#8221; said&#160;Scott Koenig, M.D., Ph.D., President and CEO of&#160;MacroGenics. &#8220;As we prepare for our first commercial launch and look forward to being able to deliver MARGENZA to patients, we continue to focus on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer with eight product candidates currently in clinical development.&#8221;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The approval for MARGENZA was based on data from SOPHIA, a randomized Phase 3 clinical trial. The study, which included 536 patients, showed a statistically significant 24% reduction in the risk of disease progression or death with MARGENZA plus chemotherapy compared with trastuzumab plus chemotherapy (hazard ratio &#91;HR&#93;&#61;0.76&#59; 95% CI, 0.59-0.98&#59; P&#61;0.033&#59; median PFS 5.8 vs 4.9 months).  The objective response rate  for MARGENZA plus chemotherapy was 22% and for trastuzumab plus chemotherapy was 16%. The final Overall Survival (OS) analysis is expected in the second half of 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverse reactions occurring in greater than twenty percent of patients with MARGENZA in combination with chemotherapy were fatigue&#47;asthenia (57%), nausea (33%), diarrhea (25%), and vomiting (21%). The MARGENZA U.S. Prescribing Information has a BOXED WARNING for left ventricular dysfunction and embryo-fetal toxicity.  In addition, MARGENZA can cause infusion related reactions (IRRs).  IRRs occurred in 13% of patients treated with MARGENZA, with the majority reported as Grade 2 or less. Grade 3 IRRs occurred in 1.5% of patients.  See below for Important Safety Information. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Early detection and treatment have had a positive impact on the survival of patients with breast cancer, but the prognosis for people diagnosed with metastatic breast cancer remains poor, and additional treatments are needed,&#8221; said&#160;Hope S. Rugo, M.D., Professor of Medicine and Director of Breast Oncology and Clinical Trials Education,&#160;University of California San Francisco Helen Diller Family </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.5pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Comprehensive Cancer Center. &#8220;As the only HER2-targeted agent to have shown a PFS improvement versus trastuzumab in a head-to-head Phase 3 clinical trial, MARGENZA with chemotherapy represents the newest treatment option for patients who have progressed on available HER2-directed therapies.&#8221;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Women with metastatic HER2-positive breast cancer are benefiting from ongoing scientific advances,&#8221; said Christine Benjamin, LMSW, Chair, Metastatic Breast Cancer Alliance.  &#8220;We are always excited to learn of additional treatment options that are available to healthcare professionals and those living with metastatic breast cancer.&#8221; </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics anticipates that MARGENZA will be available in March of 2021.</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Conference Call</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics will host a conference call for analysts and investors on Thursday, December 17, 2020, at 8&#58;00 a.m. ET. To participate in the conference call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) ten minutes prior to the start of the call and provide the Conference ID&#58; 8657888.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The listen-only webcast of the conference call can be accessed under &#34;Events &#38; Presentations&#34; in the Investor Relations section of the Company's website at </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">http&#58;&#47;&#47;ir.macrogenics.com&#47;events-and-presentations&#47;events</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.</font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About the SOPHIA Study</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The SOPHIA study (NCT02492711) is a randomized, open-label Phase 3 clinical trial evaluating MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer, who have previously been treated with anti-HER2-targeted therapies. All study patients had previously received trastuzumab, all but one patient had previously received pertuzumab, and 91% had previously received ado-trastuzumab emtansine, or T-DM1.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The study enrolled 536 patients who were randomized 1&#58;1 to receive either MARGENZA (n&#61;266) given intravenously at 15 mg&#47;kg every three weeks or trastuzumab (n&#61;270) given intravenously at 6 mg&#47;kg (or 8 mg&#47;kg for loading dose) every three weeks in combination with one of four chemotherapy agents (capecitabine, eribulin, gemcitabine or vinorelbine) given at the standard doses. Intent-to-treat PFS analysis occurred after 265 PFS events.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary endpoints of the study are sequentially-assessed PFS, determined by blinded, centrally-reviewed radiological review, followed by OS. Additional key secondary endpoints are PFS by investigator assessment, ORR and Duration of Response. Tertiary endpoints include ORR by investigator assessment and safety. PFS and ORR were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About HER2-positive Breast Cancer</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Human epidermal growth factor receptor 2 (HER2) is a protein found on the surface of some cancer cells that promotes growth and is associated with aggressive disease and poor prognosis. Approximately 15-20% of breast cancer cases are HER2-positive. Monoclonal antibodies targeting HER2 have greatly </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.5pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">improved outcomes&#59; however, a significant number of patients progress to later lines of therapy. Effective treatments for metastatic HER2-positive breast cancer continue to remain an unmet need.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About MARGENZA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MARGENZA (margetuximab-cmkb) is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors. Similar to trastuzumab, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC). However, through MacroGenics&#8217; Fc Optimization technology, margetuximab-cmkb has been engineered to enhance the engagement of the immune system. In vitro, the modified Fc region of margetuximab-cmkb increases binding to the activating Fc receptor FCGR3A (CD16A) and decreases binding to the inhibitory Fc receptor FCGR2B (CD32B).  These changes lead to greater in vitro ADCC and NK cell activation.  The clinical significance of in vitro data is unknown.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Margetuximab-cmkb is also being evaluated in combination with checkpoint blockade in the Phase 2&#47;3 MAHOGANY trial for the treatment of patients with HER2-positive gastroesophageal cancer (NCT04082364), and in combination with tebotelimab (PD-1 &#215; LAG-3 bispecific DART&#174; molecule) in various HER2-positive tumors (NCT03219268). MacroGenics is partnered with Zai Lab for the development and commercialization of margetuximab-cmkb in Greater China. For more information, please visit&#160;www.clinicaltrials.gov.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">IMPORTANT SAFETY INFORMATION</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BOXED WARNING&#58; LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Left Ventricular Dysfunction&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant decrease in left ventricular function.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Embryo-Fetal Toxicity&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exposure to MARGENZA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WARNINGS &#38; PRECAUTIONS&#58;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Left Ventricular Dysfunction</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Left ventricular cardiac dysfunction can occur with MARGENZA. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">MARGENZA has not been studied in patients with a pretreatment LVEF value of &#60;50%, a prior history of myocardial infarction or unstable angina within 6 months, or congestive heart failure NYHA class II-IV.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Withhold MARGENZA for &#8805;16% absolute decrease in LVEF from pre-treatment values or LVEF below institutional limits of normal (or 50% if no limits available) and &#8805;10% absolute decrease in LVEF from pretreatment values. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Permanently discontinue MARGENZA if LVEF decline persists greater than 8 weeks, or dosing is interrupted more than 3 times due to LVEF decline.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Evaluate cardiac function within 4 weeks prior to and every 3 months during and upon completion of treatment. Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Monitor cardiac function every 4 weeks if MARGENZA is withheld for significant left ventricular cardiac dysfunction.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.5pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Embryo-Fetal Toxicity</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Based on findings in animals and mechanism of action, MARGENZA can cause fetal harm when administered to a pregnant woman. Post-marketing studies of other HER-2 directed antibodies during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Verify pregnancy status of women of reproductive potential prior to initiation of MARGENZA.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Advise pregnant women and women of reproductive potential that exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in fetal harm.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Advise women of reproductive potential to use effective contraception during treatment and for 4 months following the last dose of MARGENZA.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Infusion-Related Reactions (IRRs)</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">MARGENZA can cause IRRs. Symptoms may include fever, chills, arthralgia, cough, dizziness, fatigue, nausea, vomiting, headache, diaphoresis, tachycardia, hypotension, pruritus, rash, urticaria, and dyspnea. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Monitor patients during and after MARGENZA infusion. Have medications and emergency equipment to treat IRRs available for immediate use.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In patients experiencing mild or moderate IRRs, decrease rate of infusion and consider premedications, including antihistamines, corticosteroids, and antipyretics. Monitor patients until symptoms completely resolve.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with supportive medical therapy as needed. Permanently discontinue MARGENZA in all patients with severe or life-threatening IRRs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MOST COMMON ADVERSE REACTIONS&#58;</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The most common adverse drug reactions (&#8805;10%) with MARGENZA in combination with chemotherapy are fatigue&#47;asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia&#47;myalgia, cough, decreased appetite, dyspnea, infusion-related reactions, palmar-plantar erythrodysesthesia, and extremity pain.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You may report side effects to the FDA at (800) FDA-1088 or </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.fda.gov&#47;medwatch</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or to MacroGenics at (844)-MED-MGNX (844-633-6469).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Link to full </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Prescribing Information,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> including Boxed Warning</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About&#160;MacroGenics, Inc.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics&#160;is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of&#160;MacroGenics'&#160;technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.macrogenics.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;MacroGenics,&#160;the&#160;MacroGenics&#160;logo and DART are trademarks or registered trademarks of&#160;MacroGenics, Inc.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.5pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cautionary Note on Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, commercial prospects of or product revenues from MARGENZA, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and other statements containing the words &#34;subject to,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;plan,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;estimate,&#34; &#34;project,&#34; &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;would,&#34; &#34;could,&#34; &#34;can,&#34; the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA&#8217;s market acceptance, competition, reimbursement and regulatory actions the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the&#160;Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Contacts&#58;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jim Karrels, Senior Vice President, CFO</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">+1-301-251-5172</font></div><div><font style="background-color:#ffffff;color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">info&#64;macrogenics.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Source&#58; MacroGenics, Inc.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Herceptin&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">is a registered trademark of Genentech </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mgnx-20201216.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:defe0dfc-b2b5-41eb-a804-8da8c22404f1,g:2b135c73-87ba-4a09-9f73-64d843511717-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20201216" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20201216">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20201216_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20201216_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20201216_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20201216_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://macrogenics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>mgnx-20201216_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:defe0dfc-b2b5-41eb-a804-8da8c22404f1,g:2b135c73-87ba-4a09-9f73-64d843511717-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20201216.xsd#Cover"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>mgnx-20201216_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:defe0dfc-b2b5-41eb-a804-8da8c22404f1,g:2b135c73-87ba-4a09-9f73-64d843511717-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20201216.xsd#Cover"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended" id="i554213e8ebb64d62a61d4a0bd51c9369_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mgnx-20201216_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:defe0dfc-b2b5-41eb-a804-8da8c22404f1,g:2b135c73-87ba-4a09-9f73-64d843511717-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_09428839-cec1-4442-83dd-c8de4c6610fd_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_79d9977e-adc0-4b6c-a1a6-5d9f5e6dec3f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6a6860f9-f208-49ca-8aaf-b284b96e832e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d138509c-7aca-47e5-bfc2-81e2f1690630_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_849166cd-9d24-4076-bd9e-71c099f5a526_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2f91a7a7-3ded-434d-970e-611c795b78b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_91899125-8f11-4206-a3a3-5e9bcf569cdb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6e42fa62-838b-481f-9568-af5487687f83_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1b670fbf-17b9-4277-91bf-568b6cc830f0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a8331e16-ad77-4ee8-a771-b93f1c89675c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_585c0e56-0082-43e7-9f01-f356488c468c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9dbd6744-cfd7-4f39-b2fb-3488baad043e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d3b0372e-9414-4d3f-95fb-bc319bf4d8cb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ea047148-7a02-4cf1-a478-02d7a681b4fc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2fe85e6f-8ca2-4d78-b18d-a2115791f601_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e885679b-49fc-4ce3-82ba-351b7e9cd6da_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_83133a19-c8d5-4ac6-a7b6-5fd69e4c8ff9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a3ddcf0f-f600-4b5e-940d-1fa725e963f3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_af81edad-a2f3-4367-8fea-6c13595d6ef6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dbc59c31-803f-48a5-962d-430e8141f454_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_92127450-3478-4207-8c62-52bf30fb6483_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_07bdc650-9470-4aa2-b7e3-4dc45a607913_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mgnx-20201216_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:defe0dfc-b2b5-41eb-a804-8da8c22404f1,g:2b135c73-87ba-4a09-9f73-64d843511717-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20201216.xsd#Cover"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_98823a64-dc72-462a-81c6-b253db96d513" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_DocumentType_98823a64-dc72-462a-81c6-b253db96d513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9c94d61d-e05d-4981-8150-f71c35874a85" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_DocumentPeriodEndDate_9c94d61d-e05d-4981-8150-f71c35874a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_aff0ede5-599b-4b93-a045-83638994f97f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityRegistrantName_aff0ede5-599b-4b93-a045-83638994f97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f8b8c12d-5fa5-47d2-8d52-a2d68c0366a4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f8b8c12d-5fa5-47d2-8d52-a2d68c0366a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a138bf00-19d5-4bb4-af02-5322a8c1e96f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityFileNumber_a138bf00-19d5-4bb4-af02-5322a8c1e96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3a71aeb0-c0b9-4df2-a3a7-22308c470fda" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityTaxIdentificationNumber_3a71aeb0-c0b9-4df2-a3a7-22308c470fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_686b19eb-ccf7-477e-a9a9-05e99e21ef6a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityAddressAddressLine1_686b19eb-ccf7-477e-a9a9-05e99e21ef6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_56a11b94-6044-47f4-908f-004b5791c87b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityAddressCityOrTown_56a11b94-6044-47f4-908f-004b5791c87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_317c8255-2fe9-4a7f-870d-3eb5ff0c7e87" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityAddressStateOrProvince_317c8255-2fe9-4a7f-870d-3eb5ff0c7e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3404b959-6265-4de5-8095-0a3887e78ee9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityAddressPostalZipCode_3404b959-6265-4de5-8095-0a3887e78ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec8e5db8-cbeb-453a-850e-70a3d94114b8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_CityAreaCode_ec8e5db8-cbeb-453a-850e-70a3d94114b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d890fbe0-5ed7-47cd-9d0c-38935295c64a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_LocalPhoneNumber_d890fbe0-5ed7-47cd-9d0c-38935295c64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_83b08708-3a4b-4e03-86cc-bc75aea6c44f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_Security12bTitle_83b08708-3a4b-4e03-86cc-bc75aea6c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_39d37868-dd51-4d00-a19c-f4c6eff0cbb0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_TradingSymbol_39d37868-dd51-4d00-a19c-f4c6eff0cbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5d7d3a02-0846-4389-b012-ea07ba2e35d1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_SecurityExchangeName_5d7d3a02-0846-4389-b012-ea07ba2e35d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_26faa73e-fa39-40eb-b221-dfbae129ffac" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_WrittenCommunications_26faa73e-fa39-40eb-b221-dfbae129ffac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ce62a3ed-d9f6-4084-b70a-c259b2a52908" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_SolicitingMaterial_ce62a3ed-d9f6-4084-b70a-c259b2a52908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_dce0bc23-193b-481f-92b7-d0c435d70ce2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_PreCommencementTenderOffer_dce0bc23-193b-481f-92b7-d0c435d70ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_53794d12-0090-4dc1-a13e-27ecc93669f2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_53794d12-0090-4dc1-a13e-27ecc93669f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2f07ebcd-9c1b-481f-bd20-a181ed50e46a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityEmergingGrowthCompany_2f07ebcd-9c1b-481f-bd20-a181ed50e46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_452d7922-e358-4317-8528-1f90fe33c3c3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_EntityCentralIndexKey_452d7922-e358-4317-8528-1f90fe33c3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3adb035d-9967-418f-a720-8c7b0da35526" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_057d9840-8d35-463c-a929-085638c55e4b" xlink:to="loc_dei_AmendmentFlag_3adb035d-9967-418f-a720-8c7b0da35526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_11.jpg
<TEXT>
begin 644 image_11.jpg
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M1D][Y5,O_M^3[>T/CI4*   (Z$!UP7RK?'I4/C8O_:>3\O&D?!R48?U$20$
M@( .Y OGA^73X(8_"RWI.UK4 0! 0 ?RA//'Y=/#!?\\A/-[6M(! *#9WE($
MT+IPOG6+<!YLWO+O 0   1VX(9QOE$^'2_S3!TH/   $=""=9^5C8XE_MU&&
M^[[B P   1U841FP]\HG(1L   1TH,9P'H+Y(R4!   ".E!?. ]=VI\EV)19
MW $ 0$ '5K#LN/-9$VNA P" @ XL:31Z&I9'ZR?8U+[2! " 9ON,(H#&AO.P
M?OF+!)L:;V]_<$^) @! LVE!AV:&\Y3CSN\K40  $-"!Y1R6CUZ"[=S?WO[
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MQO]%@T^_]4=[B@P $-!9MW#>*\Z[MJ_J-MU4 2Z(X\KO7Q7.YWA4AO0M)0<
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M %R_S%I<VNI>HI ^72-=!60]I1AW'MPW[AQHL^___J^$:^>36X3S:9!_K/0
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M>:N);RJ&Z7N)-A<J-UU??NU9D6;<N8GW *HSG ;O6X3ST/S>^]W?_;V^X@,
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M[H$"!  !/7=(3S6S> BTAVU?(]VX<X"U=E1<FBQNX<!>G/9_^]__3D\1 H"
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MN_%& 0"\87/SK[RZ1MS4I?W"$FPSS>F_]FN_(:0#@(#>FI ^+.KI8GX47QL
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MC!O?M#D 35:Y@97Q_6W.?/_6>3]LSEQSWKOMM:?\][.!=5*\OBEYW+(RZ,=
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MI.[F'H0)OE)O=]RE0!0G2$L]\5 ;6WY7.<'D[,[:5Q&_M8_*[_#>@L?_(%8
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MFWI#:1S/2;NK?*=F;DHT>2S^R<PY>+C.)X<Z OJ3A%^^XZ*&95YFUHL^27C
M[=;8TK=?XSY)>;$X:-D,^+FZN8\K^ Y,@_K]HAE++4WB<9PC%*7>3Y7<C(NS
M\><Z%BH]5\7C;1KT#HIFWAPZCD'J<S4$\_- ?GIZ/KQEL8G@%O5)@DKN<9B\
MIWQ\;N:<T89P-HGO-5SO0R"_&T-YI=>9V'USW9:_'"7\WJ6X63"NN@!BF*HJ
M# TS'4,Y>@,V;E+7>+/Q;M&<FXTG\7U,>_ <)_RLXS@6_TZL5S7A>AL^W]DU
M))Z#U_[FWF?J>-&XCNZ@.!\K&R:TZ=UR)X7'1[$"6IN9S_%^_!P;2QQPX:+P
MI.ZQY_&S;,U\EMOLDTG\'+?>)_%U'Q?G+7*])=]^>.U1W<?#DN4>RGP[?OY5
MUY>>Q(OE?M4W>^)^[,?C9Y5]N<SG'>6^,1,G17L0/]OF"L=I:-4>5KE_RO<^
M6/)[?=4Y:Q*/L>.:OSN;\9SU7E%1B_XU^_2H"?.'_/3/_.SI6>OY:=+-WMO>
M_B!+>/GXP=F*$_V:]^'E_1F.ZX_#STWK.EF65V^F[M1FQRG'ZY?E,IBYCBYU
MS:R[PC^S;]]-4!>X?,X>Y;RI5+[WV;IP?\7OWI.V=%DN/_?T^K-589WG[)I3
M]9CK\K/6<;T]CC=KCM:U&WOC OHU%>#K#O#C-HPEC97&FTZN;?DLE>^3!<OO
M3,/7.E\EZ-XV #;N>)I9W_[=^'F6N8$UZZ28N3E7-&!"Q067LSMI6J^.)8ZQ
M21LFKXS[8S,><[T$Q]R\"N0DAK?CIIU_?OJG?[9?AO/G&3;]N3*@5W)^B8$]
M[+>O%:]O*.6H^([C.>7C>$ZQ=OD:B<?1M>>T+E;X:PAT-YU_3];E>Q=OL$SK
M.N\E.G=-;UHT[H;AS,W5V>OM*DYFZW?Q\W9Z",QGG$: "D/4[$7[N@OX<3QA
MK^6-&!IYS%VHP!>ON_6UXH9J7 [M4>+-3LIP?J<AE=]I9?<V%=_9_7@BA ,-
M/7>]JO/4,=PB\6==I!%@&LA;^WD%= #@IH#^HEB]%>.R81G0=Y0N %3',FL
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MH-L!O;_DO]NTZP#HH%S=V[6> X" #@ L(G/W]@^5,  (Z # 8AYDW/98\0*
M@ X +";7^/,CRZL!@( . "Q@-'K:+Y]ZF39O>34 $- !@ 5M9]RV">( 0$ '
M !:4JWO[\?;V!Q/%"P ".@!P@]'HZ:!\VLBU>24,  (Z + 8W=L!0$ ' .H4
MUS[O9]J\[NT (* #  L:Y,S_BA< !'0 8#&ZMP. @ X U&DT>AIF;N]EVKSN
M[0 @H , "\K9>JY[.P (Z # C>GY?'*XK8PO,53* ""@ P W>Y!QVT?;VQ^<
M*&( $- !@)L-,F[[0\4+  (Z '"#T>AI".<;F38?6L[-W@X  CH L #=VP%
M0 < ZC0:/>V73YLY7T(I X" #@#<+.?2:I/M[0_&BA@ !'0 X!IQ:;5!QI=X
MHI0!0$ ' &[V(//VAXH8  1T . :H]'3,&O[(&<X-SD<  CH ,#-'A;YEE8[
MNP>@B % 0 < ;I:S>[O)X0! 0 < ;C(:/1T4>5O/30X'  (Z +" 1YFW/U3$
M ""@ P#7B*WGO9SAW.1P ""@ P WR]UZKGL[  CH ,!U*F@]'V]O?W"LI %
M0 < KI>[]=S2:@ @H , UR;G_*WG86FUH9(&  $= +B>L>< @( . '6JH/4\
MS-H^5-( (* # -?+WGIN:34 $- !@&M4T'H>#)4T  CH ,#U<K>>#[>W/Y@H
M9@ 0T & *XQ&3Q\6^5O/]Y4T  CH ,#5X7RCT'H.  CH %"[T'J^D?DUM)X#
M@( . %QE-'K:*Y\>9'X9K>< (* # #<(7=MSMYZ/%#, ".@ P%6I>?1TLWP:
M9'Z9\?;V!V.E#0 ".@!PM<<5O(:QYP @H , 5QF-GFZ53_W,+S/4>@X  CH
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M+YQ/"DNJ 0 ".@"\(71KWZSHM<)X\_O&G0,  CH S(@SM@\J?$GCS@$  1T
M+H7S$,P?5OB20^/. 0 !'0 NAO-^^718X4N&5O-=)0\ ".@ \#J<A_'FSRI\
M2>/. 0 !'0 NA?.J9VPO8CB?*'T 0$ '@/K">9@4;JST 0 !'0 NAO/-"E\V
M3 IWH/0!  $= %ZK<JWSP*1P (" #@"S1J.G8;;V084O&2:#NV=2. ! 0 <
MX1P $- !H#'A?*_B<!Z$2>&.E3X (* #P'DX#\'\40WA?*CT 0 !'0!>A_/#
MBE_6C.T @( . #6'\W$9SG>4/@ @H - ?>$\C#>_K_0!  $= .H+YY/"C.T
M@( . +6&\Q#*[POG (" #@#UAO-[EE,#  1T *@OG ?WA7, 0$ '@'K#^4X9
MSL?V   @H ,@G-<;SH?V  !0I;<5 0 -#><AF ^$<P"@*[2@ R"<O[8KG ,
M CH U!O.AV4X/[ ' ("ZZ.(.0%."^4;Y]*Q\]&L*YSOV @ @H ,@G!?%\_*Q
M*9P# %VEBSL =8?S3>$< $ +.@#-".<;PCD T'5:T &H*YQO"><   (Z /6&
M\T%Q/B%<'>'\0#@' )I(%W< J@[G=2VC%NQ8YQP $- !Z'HP#ZWE(9QO"><
M  (Z /6$\UYQWJ5]LZ:W()P# (UG##H N<-YOWQZ45,X/Q'. 8"VT((.0,YP
M/BC.N[77(83S>V4X/[8G   !'8 NA_,Z)X,3S@$  1V S@?S7E'O>/,0RN^7
MX7QB;P   CH 70WG_:*^]<VGX3RTG)_8&P! VY@D#H!4X7RO?'I>8S@?"N<
M0)MI00=@U6!>]_KFP4$9S'?M#0! 0 >@J^$\C#,/7=I[-;X-RZ@! &M!%W<
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M  CH".<AS+PHP_GT5R?ESR&D?_BW_M;_(*S3EE#>*\XG>VOR3.R7@[DQY@
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MQA7!_(V?8Y(/(69<_CYTAQ^___X_$&JZ$\@W8A!_KVAO*_G4V6SL(9SKQ@X
M(*!#[?Z??_Y+9Y-WQ=G?-Z\,YQ>&KE_\[^7_S@)[\?^S=V>Y30,! (9] WH#
M?(-R@_8""!"4_8&CL5-H45LV\>C>(+U!N$&Y@(W'F6FG:190*,3)]TE6W$TB
M,2^_9ANM7Z_NW+XIV 7YL@HA_KP8'9/F_RD @$"'Y?3EZ_<RAGH(]O*\PB_'
M>9?E^<AZ'NS-A1'VP;V[MZQA[T^0ES'$-U<DR),PA3VL+3_TE $ !#KTRJ?/
MWT:[;S>C*? 31LTO_4U=3YD67W0[Q _2E/APOW/OCBG%_S_&-V* IR /]^4*
MO453V $ $.BLEJ.CK\^*>'YUW=27?AY:?/*:]6EKVKN787L71ME/0D@]N'^W
M\DF+\;\4Y2]BE \]>0  !#HKZ>#P<[=>/<5Z"N^S9>H71\UGQ7GW\^;R46_#
M>+Q;B/8J3)5__&A'9/UYC&_'^ [75HSQC15^RZ(<  "!SGK'>ETW*=:WV[#>
M&(_SR6$>[NLI\3[M][LCWMIXKW\4HRGRPZ=/'JYUB+41GJ([Q/BU&.&K'N*B
M'   @0[S['\\:F.]26=AE_-&S?,@GQ'F\Z(^K&L/:XN/FWJTSKV]3MM@Z_6F
M=-ET]"*+[LWXNDX1G@O/MVJOH\*:<@  !#K\GKW]@Q"1W>AZV]+9T6V3@GQ>
MG#=30G[LOIGX3ZGBZ["]?HQ]K_O^OQA]C5/.<_G7UXOSM>#K&M_3A&<3=ET_
MMOLZ   "'1;T8>]@HVGJ$*1I*GPY'MG-C#/69T9]4TP\ZFU!U0)_*[ 7DX^2
M5Z:N P @T.$*[;[?+V.HQV _#]I)H^870_ZW1LWIEQ#DX?B]P[XO30  0*!#
MK[U]M]=M;M8&]U9Q-L(^9TI[K<Q[*HV0=[OTMT%>^4@  !#HL*1>O]DMLV"_
M$:,]EOF53&GGZ@SB%4;(!T;( 0 0Z-!S+U^]#<%^HPWTS13M/I6E,XPQ;G0<
M  "!#NLDG@->QF#?BO>E3^:?J&*,AYWQ!V(<  "!#DP*]^TLUC>SB.?/I'/E
MP_4S1OG0SNH   AT8-%P+[-P#]?UL:_7415?\P@OC(@# "#0@?\9\.&XMS32
MGI]GOI7]VG8/WDH:^4[W)_%^&*]3F[4! "#0@54-^J0L9H_&7ROF3[?/HWI>
M@"=A'?BIIP(                 L/1^"3  =>KJH\_U#T$     245.1*Y"
"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>mgnx-20201216_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20201216.xsd" xlink:type="simple"/>
    <context id="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-06-16</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV80L2ZyYWc6ZjE5ZTM4ZDIxOTQ3NDJhNWFhMDA5MjE0MWIxMTczOWEvdGFibGU6NmZkNTNjNmRiM2IzNDViMDkzNTE2MzAwYzhkOGVlNTUvdGFibGVyYW5nZTo2ZmQ1M2M2ZGIzYjM0NWIwOTM1MTYzMDBjOGQ4ZWU1NV8yLTEtMS0xLTA_4de58ee8-1795-4a5f-b37b-f9ccd6acbe84">0001125345</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV80L2ZyYWc6ZjE5ZTM4ZDIxOTQ3NDJhNWFhMDA5MjE0MWIxMTczOWEvdGFibGU6NmZkNTNjNmRiM2IzNDViMDkzNTE2MzAwYzhkOGVlNTUvdGFibGVyYW5nZTo2ZmQ1M2M2ZGIzYjM0NWIwOTM1MTYzMDBjOGQ4ZWU1NV8zLTEtMS0xLTA_46eec113-fea7-44b2-bc12-4906c7ce5343">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ5_e4c15bbe-5517-4b79-a2dc-f465d2ad63e8">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8yMzI_8d982d2f-37e1-48cb-ac2c-fb90385c03f1">2020-12-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjUw_19fe86e0-2e56-44e3-b5b7-8abc83acf0a8">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl8wLTAtMS0xLTA_4074cb7c-80f7-4740-bdae-6ad89555964c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl8wLTMtMS0xLTA_e6c621fa-49a8-4984-b9e3-12aa6ad12e55">001-36112</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl8wLTUtMS0xLTA_016b92ca-98b5-4701-83d4-e07e1dff6857">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl8zLTAtMS0xLTA_b3f1a7fe-0c80-4bb0-ad4d-8c1035811fbf">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl80LTAtMS0xLTA_20aeeec2-ddbd-421d-8a69-35d28a341c1d">Rockville,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl80LTEtMS0xLTA_a0a3867c-a539-4dfc-b26f-88f6a576271d">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6OTcxNmNhOTAwYzA4NGFkNDk1YTE0ZjM1MjU4MjI3OGIvdGFibGVyYW5nZTo5NzE2Y2E5MDBjMDg0YWQ0OTVhMTRmMzUyNTgyMjc4Yl80LTMtMS0xLTA_4515f784-93ed-432f-99ef-d238214e6418">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ2_88e9ca61-7427-4307-801e-d1f465774bc4">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ3_40d7ff8e-c1ac-488c-94e5-ed509c9bfed0">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6ZTZmNGM4Y2UwZjEzNDVkYWFlMTZlNTA2MTc5N2I5ZmEvdGFibGVyYW5nZTplNmY0YzhjZTBmMTM0NWRhYWUxNmU1MDYxNzk3YjlmYV8xLTAtMS0xLTA_e970cd82-c104-4e86-bff3-5d9386d92280">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6ZTZmNGM4Y2UwZjEzNDVkYWFlMTZlNTA2MTc5N2I5ZmEvdGFibGVyYW5nZTplNmY0YzhjZTBmMTM0NWRhYWUxNmU1MDYxNzk3YjlmYV8xLTEtMS0xLTA_c48716b2-2061-43ac-b981-489c24aaec89">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGFibGU6ZTZmNGM4Y2UwZjEzNDVkYWFlMTZlNTA2MTc5N2I5ZmEvdGFibGVyYW5nZTplNmY0YzhjZTBmMTM0NWRhYWUxNmU1MDYxNzk3YjlmYV8xLTItMS0xLTA_d8905fc2-c4e1-4f6a-aea6-6ff2c0c371e0">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ0_afca1318-c3a1-480b-9e27-d5821fcb1f33">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ4_fdc7c2bf-de13-4ba4-866f-0e8182afc471">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQ1_de81a556-534b-4b80-8a48-1231935b6e69">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQy_38654b7b-4bd5-421a-84a4-160c72964281">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i83801ae740b4433a80db6b9c829298f1_D20200616-20200616"
      id="id3VybDovL2RvY3MudjEvZG9jOjk3ZDcwNmQ3ZTc4NTQ0NDNhZGE3OGMxYjE4YjkwYzlhL3NlYzo5N2Q3MDZkN2U3ODU0NDQzYWRhNzhjMWIxOGI5MGM5YV8xL2ZyYWc6OGExZjgyZGZiNWNmNGU2ZTgwMmFkZWUwMDM1NGEwMmYvdGV4dHJlZ2lvbjo4YTFmODJkZmI1Y2Y0ZTZlODAyYWRlZTAwMzU0YTAyZl8xNjQz_d4578305-f255-4db0-810e-020bf955273e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140522994929384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 16,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( '*+D%$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !RBY!1.6:*^^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*$Y8"R;U9:6G#08K;.QF;+4UBV-C:R1]^R5>FS*V!]C1TN]/
MGT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2.27ZJ7GPT2F:GO$(0>D/
M=42HJVH%#DD910IF8!$6(I.MT4)'5.3C!6_T@@^?L<LPHP$[=-A3 EYR8'*>
M&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#DW.33MP>'MZ?,GK%K9/
MI'J-TZ]D!9T#;MAU\FOSL-WOF*RKNBIX7?#5GJ]%O1;-_?OL^L/O)NR\L0?[
MCXVO@K*%7W<AOP!02P,$%     @ <HN049E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MC9*8>=2(!!UZT:%7F'G0<BV@N(D_"PM&IE:$!C\M?R8+'F8:LE6)A2L-59*
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M%     @ <HN048.II0/4 0  ,@8   T   !X;"]S='EL97,N>&ULU57;BM1
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ <HN04:K$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !RBY!199!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ <HN049E<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !RBY!1X>L!:#,$   T$   &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ <HN048.II0/4 0
M,@8   T              ( !=PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !RBY!1EXJ[',     3 @  "P              @ %V#@  7W)E;',O+G)E
M;'-02P$"% ,4    " !RBY!1JL0B%C,!   B @  #P              @ %?
M#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ <HN0420>FZ*M    ^ $
M !H              ( !OQ   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ <HN04660>9(9 0  SP,  !,              ( !I!$
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  [A(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mgnx-20201216.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mgnx-20201216.htm">mgnx-20201216.htm</File>
    <File>margenzaapprovalpressrelea.htm</File>
    <File>mgnx-20201216.xsd</File>
    <File>mgnx-20201216_cal.xml</File>
    <File>mgnx-20201216_def.xml</File>
    <File>mgnx-20201216_lab.xml</File>
    <File>mgnx-20201216_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20201216.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20201216_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20201216_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20201216.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20201216_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20201216_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20201216.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20201216",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201216.htm",
      "contextRef": "i83801ae740b4433a80db6b9c829298f1_D20200616-20200616",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://macrogenics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20201216.htm",
      "contextRef": "i83801ae740b4433a80db6b9c829298f1_D20200616-20200616",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001125345-20-000160-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-20-000160-xbrl.zip
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MJC;Q?*!#50"E36!X_K2UW3SX=7_V;\=ZH%.QM]=HO=B@_>:D4!#$]P+HSE*
MGD@O-F]4J+U$=,/09*&G$O'ZL"NZ412;&QD(,Q0GW8LW_=-_=_,E?Y,5[C1:
M6Y^QQH/(6#FP'ZM IOI&':0FVJ]W&KM+R'0@$T4C/'EY=?)-5_N9\!1#$XMS
M+!-R(A%3G8[%>:Q2)WA.5"J3%-]ZXFW_HET_YZW=*/$*-R2IZ$F /Q95RBAH
M I(F?KGP7;ZS2/H^Q%H]4,-TO[.-U3++ZM#'4O;K+2LD/A,65WH",CA54W%A
M)C+\.I@\?[K;;F\??"=T\$C[.L7MWF<04QE*K4TF07"!HV^Q1G)0I=DM!.:@
M[DVN!^M")R(=*S'4,3#$:$OY)N 3UV,9S41JQ%@"C7I"/(,O\&L4JR0!V=:'
ML5(BR>(;3=RT=O[Z<EV :I,L$6]5[*DHU2&DP\[F@5A+8Y!!]C'#[.LU 7$[
M%IZ9#+ +WQ*3-U83XZ:M"1T**4@)U5-3I]_B? P&$!WA8>?$%B*-M0P>B>9[
M$@T(1$86\8P2BS%),FL9TDA"$$&Q4&"[!!)6^EF0BJ@B."9WI$642XN!E1:>
ME1;3L:.^6'E*$_6E4R,PR<3$"I2H\:<,4UVG07#3"&@*DYJ0J0AX'!,J6L)T
MK+VQF,J$5UB:W-<)[E./1/0=B.@\-G[F 1,2FG?,>/)TQ,H"E'0B8UP$;F"2
MMA[A_QW@WS/A4,4*C 1V"@*1@%?!B@ _,<'5.(L37X)I#\%;DP&XK;53LPX"
MV&?W^=.MW8,F_FY,&J)_=2^&JM;U'!_+-?J/-:DOSGJ_OS\Z/N[7Q,GALHW"
M-RI9B35Q%'H-:\VNG4I YR^&@CAY<_HOZ"PI!MI$8QE/I*<R-LU(($8RG &D
M7I8 M)"+OKI1@8G(#Y.A3W=,H NAJO1'NJ9ABMZPL0<I%AHO(#>0N8.<K3I9
M>;GVY4F2Y5+52L@:]#.0B,>M?4M/ GMT][O&94.\-L;G51S&V4AT?;AB.H$F
M9@&^!EMX'?)U+N,+:UC\-TO[AGB :SO\[SL08UFGSHVNR G) @/#V$S*1$ER
MIK5S0#=.-#OWD8[8#_B^/L#R330@-Y1;+*B68&P)%A22R*%*9TQM:C@$=W@S
M("D!.21V5[3K2-\82+7"F+L\.W][U+6F7./+O(,?[9Y#WC</*MLON8]L*85"
MW7J@;" ),ZLD)8(D&BR[HH!/S5(T3&H3IZ#H@.S=%-R )W&#"*&B2DP5,0/"
M$"^1<I5S<G9KB ]8'H8>@<75, L*'ITS))@LDG%%%Z=CK![&N8]U *-3!6TA
MF4IU+!B*6B4U*Q@9O;#Q9[0W'BR0,PPC16P"1:.-5<#"K[QIK!8LR?,4D*DQ
M2%L'(!SMV\$O/:@1\;O!0R/([,9AHP9*L;] 2IJT/A-8KW\&Z-N'2O,TA$-3
MEW8!GE$108. 8++8L=Q<(,]-$U\$QES3C5,9^P3K@6(!/L">\,D'QV'3<W2G
MI@!IC:;R0$ ZS/AFU@5?I@G^IOBWXI7)M) D^,;7/E";""^+H?]!7BS,<[?)
MK8I&:N0H6&7.J[ <<U..A(KXP9:EE3-6II"^C@$+B,V/ZC[OT<HS1_I6;^C0
M"S(?3VQUMDLX3L9FRF3.#)BP]@=@$ST*-0D[P*.]^0R$3D@@?F6^@B[3R34A
MS.F>LOM,JLT'3L<6C<6VH@#D4U:UULJ(<T>YY$DON7=M+#\2#;.2!S_LM0[>
M7N!7Y^#YT^W60;.QLPVK9N] [&T]$[VCFF@VMO;JS<;>KKU\[FYK=CKVPD3Y
M&J(-SKW8:NR*FT1L-O;(=DG'R7I#, 3-X$_E,25C;Y$)L5&20***K\7%$@;;
M[6?,'DSG#VZ-[FYM/[-(&VJRF\[ E63<7A9!B+/+=0PG@UD"88/_U&V$I>6"
M#LA6X%4?AD8PS-V/E58\79\B*HI%*!$6)(M'C&TE""0]Q=](0@!'Z13$.A,1
MQ5ZLG*@:8G-M]0GC#B*-Y":^'67J^=/-G0/@90P9*\7:ULXS&,.AA+V+3YT.
M?0*%Q/&8/K>WZ#/A\P:<Q[IPK=UZMFZ15BR K5.2Z5ZL!W3340C\3^QRV"05
MK\[^U3\4'[H7IT>G;Y@ZR+\1-]A.K+TLD.">63*$!.>'6#%-!E!,==@AQ.#F
M%DHNG8%$C_ U7"2ZKS9? Y@6_V,; ,<P8X[D."QH90[LM:.+"R9S^NU ;XFI
MU7E6@7 >":U NN98%GN?R#]-C/5@<-+[)$P2\2:6OA)MP;M+H,#LA<Z2Z1I;
ME?FPI$L%$QJR?,K0.<K-"7%I+;$22%>:PIW.[LL8 M57J9HC=*[SV#$82Y+
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MF!F+VX ,?1F[VIX8_F:2<D6)) =?\CR8=]N=?^(D- 3@B')&=$!!42G64.J
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MK<LO@ >MX,VX_AUZ%K8U=KG;-M:@WUDW\[WNZPR;QCX;_ !02P,$%     @
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M#PM^D7N3_^X 9@=*@/#EM^3-&^]6/P%02P,$%     @ <HN046=]468' @
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M,\>(^RG4>17?E_$7S+I+&ZR,&8L$J(I$6L-P 8J2I%D0RFCIC!H1@ ?&!Y'
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M0/?2/99_L/-O4$L! A0#%     @ <HN04=0\8DYE'0  ;HH  !X
M     ( !     &UA<F=E;GIA87!P<F]V86QP<F5S<W)E;&5A+FAT;5!+ 0(4
M Q0    ( '*+D%$.@I,*@A0  $J%   1              "  :$=  !M9VYX
M+3(P,C Q,C$V+FAT;5!+ 0(4 Q0    ( '*+D%%JMC6$BP(  '0)   1
M          "  5(R  !M9VYX+3(P,C Q,C$V+GAS9%!+ 0(4 Q0    ( '*+
MD%&'KN0[@P$  ,0"   5              "  0PU  !M9VYX+3(P,C Q,C$V
M7V-A;"YX;6Q02P$"% ,4    " !RBY!19WU19@<"  !I!@  %0
M    @ '"-@  ;6=N>"TR,#(P,3(Q-E]D968N>&UL4$L! A0#%     @ <HN0
M4<IZ+M=9"@  HET  !4              ( !_#@  &UG;G@M,C R,#$R,39?
M;&%B+GAM;%!+ 0(4 Q0    ( '*+D%$9"-E2J08  &0Q   5
M  "  8A#  !M9VYX+3(P,C Q,C$V7W!R92YX;6Q02P4&      < !P#6 0
&9$H

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
